Meutia Diva Hakim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Meutia Diva Hakim has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Hee Kang
Humanitas College, Kyung Hee University, 1732 Deogyeongdae-ro, Yongin 17104, Republic of Korea
3 shared publications - Kantawong Kawalin
Department of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Republic of Korea
3 shared publications - Phuong Thi Ho
Department of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Republic of Korea
3 shared publications - Taek-Kyun Lee
Risk Assessment Research Center, Korea Institute of Ocean Science & Technology, Geoje 53201, Republic of Korea
3 shared publications - Eulyong Park
R&D Center, Easthill Corporation, Suwon 16642, Republic of Korea, Republic of Korea
2 shared publications - Sukchan Lee
Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Republic of Korea
2 shared publications
Latest Publications
- Open Access
Therapeutic Potential of Polydatin Against Cancer Cachexia by Regulating the STAT3 Signaling Pathway
Background/Objectives: Cancer cachexia is a wasting syndrome with significant loss of body weight and muscle mass caused by inflammation and abnormal metabolism in advanced cancers. Despite its detrimental effects on patients, no standard treatment has been established for this syndrome. Thus, finding new treatments will broaden the remedy for cancer cachexia, resulting in increased survival in patients with terminal cancer. Methods: In this study, we assessed the therapeutic effects of the natural compound polydatin on cancer cachexia in vitro and in vivo using C2C12 myoblasts and CT26-bearing mice to elucidate the mechanisms of how it ameliorates muscle atrophy. At the same time, molecular docking analysis of polydatin with the IL6/STAT3 signaling pathway was conducted to demonstrate their interaction. Results: Our data showed that polydatin treatment at 100 mg/kg could attenuate symptoms of cancer cachexia including body weight loss, muscle strength and severe inflammation. Muscle mass reduction—with the shrinking of muscle fibers, an increase in the expression levels of two E3 ubiquitin ligases (MuRF1 and Atrogin-1) and interleukin-6, and a downregulation of MyHC—observed in CT26-bearing mice was reversed by polydatin at 100 mg/kg. On C2C12 myotubes, polydatin also ameliorated muscle atrophy induced by the CT26 conditioned medium and suppressed STAT3 phosphorylation at the concentration of 200 µM. Structural features of polydatin in the proteins in the STAT3 pathway were identified through molecular docking simulations. Conclusions: Taken together, polydatin significantly attenuated muscle atrophy in a cancer cachexia model by inhibiting the STAT3 signaling pathway; thus, it might be a promising compound in the development of drug candidates for cancer cachexia therapy.
Open AccessTherapeutic Potential of Polydatin Against Cancer Cachexia by Regulating the STAT3 Signaling Pathway
Background/Objectives: Cancer cachexia is a wasting syndrome with significant loss of body weight and muscle mass caused by inflammation and abnormal metabolism in advanced cancers. Despite its detrimental effects on patients, no standard treatment has been established for this syndrome. Thus, finding new treatments will broaden the remedy for cancer cachexia, resulting in increased survival in patients with terminal cancer. Methods: In this study, we assessed the therapeutic effects of the natural compound polydatin on cancer cachexia in vitro and in vivo using C2C12 myoblasts and CT26-bearing mice to elucidate the mechanisms of how it ameliorates muscle atrophy. At the same time, molecular docking analysis of polydatin with the IL6/STAT3 signaling pathway was conducted to demonstrate their interaction. Results: Our data showed that polydatin treatment at 100 mg/kg could attenuate symptoms of cancer cachexia including body weight loss, muscle strength and severe inflammation. Muscle mass reduction—with the shrinking of muscle fibers, an increase in the expression levels of two E3 ubiquitin ligases (MuRF1 and Atrogin-1) and interleukin-6, and a downregulation of MyHC—observed in CT26-bearing mice was reversed by polydatin at 100 mg/kg. On C2C12 myotubes, polydatin also ameliorated muscle atrophy induced by the CT26 conditioned medium and suppressed STAT3 phosphorylation at the concentration of 200 µM. Structural features of polydatin in the proteins in the STAT3 pathway were identified through molecular docking simulations. Conclusions: Taken together, polydatin significantly attenuated muscle atrophy in a cancer cachexia model by inhibiting the STAT3 signaling pathway; thus, it might be a promising compound in the development of drug candidates for cancer cachexia therapy.
- Open Access
- 3 June 2025
- Published by MDPI AG in Preprints.org
Valproic Acid Enhances the Anti‐Cancer Effect of L‐Ascorbic Acid by Upregulating Sodium‐Dependent Vitamin C Transporter 2 in Colorectal Cancer
Vitamin C, also known as L-ascorbic acid (AA), functions as a pro-oxidant in cancer at high doses and exerts anti-cancer effects by generating reactive oxygen species (ROS) and selectively damaging cancer cells. However, low-dose AA reportedly promotes cell proliferation. Accordingly, the effectiveness of high-dose AA therapy is governed by the level of sodium-dependent vitamin C transporter 2 (SVCT2), as it regulates AA uptake. In a neuronal model, valproic acid (VPA) increased SVCT2 expression and enhanced AA uptake. Therefore, we examined the potential anti-cancer effects of VPA and AA in cells with low SVCT2 expression, including HCT-116 and DLD-1 colorectal cancer cells. In both cell lines, VPA increased the SVCT2 expression. Co-treatment with AA and VPA increased the apoptotic cells, and intracellular AA uptake and ROS generation were enhanced in both cancer cell lines. Co-treatment with AA and VPA exerted a synergistic anti-cancer effect, suppressing the hormetic dose response of AA in both cell lines. In shSVCT2-silenced cells, VPA significantly increased SVCT2 expression. The co-treatment reduced intracellular AA uptake, ROS generation, apoptosis rates, and anti-cancer effects in shSVCT2 cells. In a xenograft mouse model, the co-treatment decreased the tumor size and increased the percentage of tumor growth inhibition ratio compared with treatment with AA or VPA alone. In addition, VPA and the co-treatment increased mSVCT2 expression in the tumor. Accordingly, VPA treatment could enhance SVCT2 expression in colorectal cancer cells, suppressing the hormetic dose-response effect of AA and improving the potential of high-dose AA therapy as an anti-cancer agent.
- 3 June 2025
- Published by MDPI AG in Preprints.org
Open AccessValproic Acid Enhances the Anti‐Cancer Effect of L‐Ascorbic Acid by Upregulating Sodium‐Dependent Vitamin C Transporter 2 in Colorectal Cancer
Vitamin C, also known as L-ascorbic acid (AA), functions as a pro-oxidant in cancer at high doses and exerts anti-cancer effects by generating reactive oxygen species (ROS) and selectively damaging cancer cells. However, low-dose AA reportedly promotes cell proliferation. Accordingly, the effectiveness of high-dose AA therapy is governed by the level of sodium-dependent vitamin C transporter 2 (SVCT2), as it regulates AA uptake. In a neuronal model, valproic acid (VPA) increased SVCT2 expression and enhanced AA uptake. Therefore, we examined the potential anti-cancer effects of VPA and AA in cells with low SVCT2 expression, including HCT-116 and DLD-1 colorectal cancer cells. In both cell lines, VPA increased the SVCT2 expression. Co-treatment with AA and VPA increased the apoptotic cells, and intracellular AA uptake and ROS generation were enhanced in both cancer cell lines. Co-treatment with AA and VPA exerted a synergistic anti-cancer effect, suppressing the hormetic dose response of AA in both cell lines. In shSVCT2-silenced cells, VPA significantly increased SVCT2 expression. The co-treatment reduced intracellular AA uptake, ROS generation, apoptosis rates, and anti-cancer effects in shSVCT2 cells. In a xenograft mouse model, the co-treatment decreased the tumor size and increased the percentage of tumor growth inhibition ratio compared with treatment with AA or VPA alone. In addition, VPA and the co-treatment increased mSVCT2 expression in the tumor. Accordingly, VPA treatment could enhance SVCT2 expression in colorectal cancer cells, suppressing the hormetic dose-response effect of AA and improving the potential of high-dose AA therapy as an anti-cancer agent.
- Open Access
Amelioration of Cancer Cachexia by Dalbergia odorifera Extract Through AKT Signaling Pathway Regulation
Background/Objectives: Cancer cachexia is a multifactorial syndrome characterized by the progressive loss of skeletal muscle mass and adipose tissue. Dalbergia odorifer is widely used in traditional medicine in Korea and China to treat various diseases. However, its exact role and underlying mechanism in regulating cancer cachexia have not been elucidated yet. This research was conducted to investigate the effect of D. odorifer extract (DOE) in preventing the development of cancer-induced cachexia symptoms and figure out the relevant mechanisms. Methods: A cancer cachexia model was established in Balb/c mice using the CT26 colon carcinoma cell line. To evaluate the anti-cachexia effect of Dalbergia odorifer extract (DOE), CT26-bearing mice were orally administered with DOE at concentrations of 50 and 100 mg/kg BW for 14 days. C2C12 myotubes and 3T3L1 adipocytes were treated with 80% CT26 conditioned medium, DOE, and wortmannin, a particular AKT inhibitor to determine the influence of DOE in the AKT signaling pathway. Mice body weight, food intake, myofiber cross-sectional area, adipocyte size, myotube diameter, lipid accumulation, and relevant gene expression were analyzed. Results: The oral administration of DOE at doses of 50 and 100 mg/kg body weight to CT26 tumor-bearing mice resulted in a significant reduction in body weight loss, an increase in food intake, and a decrease in serum glycerol levels. Furthermore, DOE treatment led to an increase in muscle mass, larger muscle fiber diameter, and elevated expression levels of MyH2 and Igf1, while simultaneously reducing the expression of Atrogin1 and MuRF1. DOE also attenuated adipose tissue wasting, as evidenced by increased epididymal fat mass, enlarged adipocyte size, and upregulated Pparγ expression, alongside a reduction in Ucp1 and IL6 levels. In cachectic C2C12 myotubes and 3T3-L1 adipocytes induced by the CT26 conditioned medium, DOE significantly inhibited muscle wasting and lipolysis by activating the AKT signaling pathway. The treatment of wortmannin, a specific AKT inhibitor, effectively neutralized DOE’s impact on the AKT pathway, myotube diameter, and lipid accumulation. Conclusions: DOE ameliorates cancer cachexia through the expression of genes involved in protein synthesis and lipogenesis, while suppressing those related to protein degradation, suggesting its potential as a plant-derived therapeutic agent in combating cancer cachexia.
Open AccessAmelioration of Cancer Cachexia by Dalbergia odorifera Extract Through AKT Signaling Pathway Regulation
Background/Objectives: Cancer cachexia is a multifactorial syndrome characterized by the progressive loss of skeletal muscle mass and adipose tissue. Dalbergia odorifer is widely used in traditional medicine in Korea and China to treat various diseases. However, its exact role and underlying mechanism in regulating cancer cachexia have not been elucidated yet. This research was conducted to investigate the effect of D. odorifer extract (DOE) in preventing the development of cancer-induced cachexia symptoms and figure out the relevant mechanisms. Methods: A cancer cachexia model was established in Balb/c mice using the CT26 colon carcinoma cell line. To evaluate the anti-cachexia effect of Dalbergia odorifer extract (DOE), CT26-bearing mice were orally administered with DOE at concentrations of 50 and 100 mg/kg BW for 14 days. C2C12 myotubes and 3T3L1 adipocytes were treated with 80% CT26 conditioned medium, DOE, and wortmannin, a particular AKT inhibitor to determine the influence of DOE in the AKT signaling pathway. Mice body weight, food intake, myofiber cross-sectional area, adipocyte size, myotube diameter, lipid accumulation, and relevant gene expression were analyzed. Results: The oral administration of DOE at doses of 50 and 100 mg/kg body weight to CT26 tumor-bearing mice resulted in a significant reduction in body weight loss, an increase in food intake, and a decrease in serum glycerol levels. Furthermore, DOE treatment led to an increase in muscle mass, larger muscle fiber diameter, and elevated expression levels of MyH2 and Igf1, while simultaneously reducing the expression of Atrogin1 and MuRF1. DOE also attenuated adipose tissue wasting, as evidenced by increased epididymal fat mass, enlarged adipocyte size, and upregulated Pparγ expression, alongside a reduction in Ucp1 and IL6 levels. In cachectic C2C12 myotubes and 3T3-L1 adipocytes induced by the CT26 conditioned medium, DOE significantly inhibited muscle wasting and lipolysis by activating the AKT signaling pathway. The treatment of wortmannin, a specific AKT inhibitor, effectively neutralized DOE’s impact on the AKT pathway, myotube diameter, and lipid accumulation. Conclusions: DOE ameliorates cancer cachexia through the expression of genes involved in protein synthesis and lipogenesis, while suppressing those related to protein degradation, suggesting its potential as a plant-derived therapeutic agent in combating cancer cachexia.